Overview
- AbbVie reports results later this month, creating a near-term test for a stock that is down about 10% this year.
- Management guides to adjusted earnings of $13.96 to $14.16 per share for 2026, up from $10.00 last year.
- Sales of newer drugs Skyrizi and Rinvoq, plus recent acquisitions, are driving growth that helps replace lost Humira revenue.
- The headline price-to-earnings ratio looks high at about 88 because of one-time acquisition costs, while analyst forecasts imply roughly 14 times earnings.
- The dividend yields about 3.3% after a decade of raises, appealing to income investors who want steady cash payouts.